While Zepatier – a combination of the protease inhibitor grazoprevir and NS5A inhibitor elbasvir, approved by FDA and launched in January – may not represent a great threat to Gilead's Harvoni (sofosbuvir/ledipasvir) and AbbVie's Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) on its own merits, the impact of a third and clearly cheaper regimen is weighing on both companies, especially with changes coming to the US HCV market. Access is being broadened to less-sick patients, which means more patients but shorter durations of therapy, as well as to VA and Medicaid patients, where steep discounts come into play.
Zepatier was approved by FDA on Jan. 28 and Merck immediately changed the game in terms of pricing. It set...




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
